| All adult patients# | Adults excluding patients with chronic lung disease¶ | Patients aged 18–50 years+ | Patients aged >50 years§ | |||||
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Age >50 years versus 18–50 years | 1.63 (1.15–2.30) | 0.006 | 1.96 (1.37–2.85) | <0.001 | ||||
| Chronic lung disease | 1.54 (1.10–2.15) | 0.012 | 1.45 (1.03–2.05) | 0.035 | ||||
| Chronic heart disease | 1.49 (1.01–2.22) | 0.049 | 1.69 (1.14–2.48) | 0.008 | ||||
| Serotype 1 | 0.63 (0.40–1.01) | 0.054 | 0.53 (0.3–0.93) | 0.026 | ||||
| Serotype 3 | 1.97 (1.23–3.16) | 0.005 | 2.52 (1.44–4.4) | 0.001 | 2.39 (1.45–3.93) | <0.001 | ||
| Serotype 19A | 2.24 (1.14–4.42) | 0.020 | 2.58 (1.14–5.82) | 0.023 | 4.32 (1.38–13.51) | 0.012 | ||
| Serotype 19F | 3.55 (1.22–10.28) | 0.020 | 3.7 (1.08–12.69) | 0.037 | 9.82 (1.06–90.78) | 0.044 | 3.45 (1.11–10.73) | 0.032 |
| Heavy consumption of alcohol | 2.26 (1.29–12.25) | 0.010 | ||||||
#: odds ratios were adjusted for age, sex, smoking, alcohol consumption, previous pneumococcal vaccination, period of influenza epidemic, serotype (1, 3, 19A, 19F, 23A and 23F) and comorbidities associated with respiratory failure (chronic lung disease, chronic heart disease, cerebrovascular disease, solid cancer and HIV infection); ¶: odds ratios were adjusted for age, sex, smoking, alcohol consumption, previous pneumococcal vaccination, period of influenza epidemic, serotypes (1, 3, 19A, 19F, 23A and 23F) and comorbidities associated with respiratory failure (chronic heart disease, cerebrovascular disease, solid cancer and HIV infection); +: odds ratios were adjusted for sex, smoking, alcohol consumption, previous pneumococcal vaccination, period of influenza epidemic, serotypes (1, 3, 19A and 19F) and comorbidities associated with respiratory failure (chronic lung disease, cerebrovascular disease and HIV infection); §: odds ratios were adjusted for sex, smoking, alcohol consumption, previous pneumococcal vaccination, period of influenza epidemic, serotypes (1, 3, 19A and 19F) and comorbidities associated with respiratory failure (chronic lung disease and cerebrovascular disease).